Study details
Enrolling now
REGENERATE-PD Trial
AskBio Inc
NCT IDNCT06285643ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
127
Study length
about 4.2 years
Ages
45–75
Locations
27 sites in CA, CO, DC +14
What this study is about
This trial is testing a treatment called AAV2-GDNF gene therapy for adults with moderate Parkinson's Disease. The treatment involves delivering the gene to the putamen, and it will be compared to control surgery.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AAV2-GDNF gene therapy
- 2.Undergo control surgery
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Change from baseline to Month 18 on PD Motor Diary
Body systems
Neurology